β2-adrenoceptor agonists in asthma and COPD treatment
Journal Title: Przewodnik Lekarza - Year 2006, Vol 84, Issue 2
Abstract
The basic symptom of asthma and COPD is bronchospasm, wchich is a result of chronic inflammation. In the treatment of airflow disturbances inhaled short- and long-acting β2-agonists are adhibited in the first place. The effect of β2-agonists therapeutic action is a result of β2-adrenergic receptors distribution. Inhaled β2-agonists differ in selectivity, receptor activation and the beginning and duration of activity. When combined with inhaled corticosteroids they improved lung function, and reduced symptoms and exacerbations more than an increased dose of corticosteroids. The most common side effects which occur during long-term treatment are: muscle tremor, tachycardia, hypoxemia and hypocaliemia (metabolic activity).
Authors and Affiliations
Małgorzata Kołaczkowska
Keywords
Related Articles
- EP ID EP123566
- DOI -
- Views 65
- Downloads 0
Metabolic syndrome - epidemic of the 21-st century, a new definition and therapeutic goals
Worldwide mortality and morbidity from cardiovascular diseases and type 2 diabetes are strictly connected with growing tide of obesity, unhealthy diet, and physical inactivity. This cluster of risk factors is known as th...
Venous thromboembolism
Venous thromboembolism (VTE) is one of the most important problems of contemporary medicine. It is connected with the fact, that this disease is common and in the case of the adverse effect of deep vein thrombosis, can...
Arterial hypertension complicated with chronic heart failure - do need change therapy?
Arterial hypertension is now one of the most serious clinical problems. Essential hypertension with ischemic heart disease is responsible for about 60% cases of chronic heart failure (CHF). The main factor, which is lead...
II Zimowe Warsztaty Sekcji Dermatologicznej Polskiego Towarzystwa Alergologicznego – Ustka 9–12 lutego 2006 r.
Co nowego w astmie oskrzelowej?
Lepsze zrozumienie mechanizmów zapalnych w astmie pozwala na poszukiwanie nowych celowanych leków. W pracy przedstawiono zarejestrowane ostatnio leki oraz kierunki prowadzonych badań.